CBLL Ceribell, Inc.

NASDAQ
$25.97

Ceribell, Inc. (CBLL) is expected to report earnings on February 2, 2027, after the market close. The consensus earnings estimate is a loss of $0.50 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +17.8% since its last earnings release on November 3, 2026.

Ceribell Beat Consensus Estimates, Narrows Guidance
Tuesday, November 3, 2026 · 4:05 PM ET
Earnings Date
4th Quarter, Dec 2026
Feb 2
Tuesday · 4:05 PM ET
Earnings Whisper
-
vs ($0.50)
Rev est $32.01M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $26.79

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Ceribell, Inc.

CeriBell Inc. is a commercial-stage medical technology company. It focused on transforming the diagnosis and management of patients with serious neurological conditions. The company is an AI-powered, rapidly deployable point-of-care electroencephalography platform designed to address the unmet needs of patients in the acute care setting. CeriBell Inc. is based in Sunnyvale, Calif.

Sector

Healthcare

Industry

Medical Instruments/Supply

Held By 1 ETFs, by dollar flow

Charts powered in part by Lightweight Charts™ by TradingView.